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Genetic variation in the human genome is an emerging resource for studying cancer, a complex set of diseases characterised by both
environmental and genetic contributions. The number of common germ-line variants is great, on the order of 10–15 million per
person, and represents a remarkable opportunity to investigate the aetiology, interindividual differences in treatment response and
outcomes of specific cancers. The study of genetic variation can elucidate critical determinants in environmental exposure and cancer,
which could have future implications for preventive and early intervention strategies. However, we are in the initial stages of
characterising the tools (i.e., the single-nucleotide polymorphism, SNP) to rigorously analyse the genetic contributions to complex
diseases, such as cancer. If the promise of the genomic era is to be realised, we must integrate this information into new strategies for
implementation in both public health measures and, most importantly, provision of individual cancer-related care.
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GENETIC VARIATION IN THE HUMAN GENOME
In the process of generating a draft sequence of the human
genome, it has become clear that the extent of genetic variation is
much larger than previously estimated (Lander et al, 2001; Venter
et al, 2001). The most common sequence variation in the human
genome is the stable substitution of a single base, the single-
nucleotide polymorphism (SNP). By definition, a SNP has a minor
allele frequency of greater than 1% in at least one population
(Risch, 2000). Most SNPs are ‘silent’ and do not alter the function
or expression of a gene. It makes sense to conceptually reserve the
term ‘mutation’ for rare variants with a particularly high
penetrance, usually associated with a detrimental phenotype, such
as a classical monogenic disorder (e.g., sickle cell disease or
haemophilia). For the purposes of this review, the focus will be on
SNPs with low penetrance or no phenotypic effect.
The total number of SNPs in the human genome is estimated to
be more than 10 million (Botstein and Risch, 2003) and the
number of SNPs with a minor allele frequency over 10% is
estimated to be perhaps as many as five million (Kruglyak and
Nickerson, 2001). Single-nucleotide polymorphisms are distribu-
ted throughout the human genome, at an estimated overall
frequency of at least on in every 1000 base pair (bp) (Carlson
et al, 2003), but with marked regional differences. Single-
nucleotide polymorphisms arise because of point mutations that
are selectively maintained in populations. Single-nucleotide
polymorphism frequencies are determined by: (1) the amount of
time since the mutation occurred; (2) evolutionary pressure on
biologically significant variants and those linked to the functional
variant; (3) random genetic drift and (4) bottleneck events.
Single-nucleotide polymorphisms in the same chromosomal
region are not inherited randomly, but as combinations of alleles,
which form haplotype blocks. It appears that the genome is
organised into distinct blocks of linkage disequilibrium (LD),
intercepted by regions in which LD breaks down rapidly (Bonnen
et al, 2002; Sabeti et al, 2002). Thus, the complexity of analysing
SNPs in a gene or locus can be reduced by the analysis of markers
inherited on a haplotype. Practically, haplotypes can be inferred by
LD analysis of a region in unrelated subjects, or characterised
molecularly in family pedigrees (see Figure 1). It is notable that
both the frequency of SNPs and the extent of LD may vary
significantly between populations. In addition, there are many
population private variants (Carlson et al, 2003).
SNPS AND PHENOTYPE
As the age of genomics proceeds forward in search of genetic
variants (i.e. SNPs) that influence disease susceptibility and outcome,
a great effort has been directed at picking SNPs for study. The
promise of utilising biallelic SNPs for whole genome linkage studies,
though very exciting in theory, is still some time off in the future
because of issues related to the prohibitive cost and impracticality of
genotyping the required thousands of SNPs, not to mention
developing the databases and analytical tools needed to interpret
the data (Kruglyak, 1999). Still, we can count on this approach in the
future, but for now, because of limited resources and analytical tools,
most investigators will continue to utilise a strategy that investigates
specific genes, known as the candidate gene approach.
The candidate gene approach examines SNPs, chosen from
genes that ‘make sense’. In other words, they fit a plausible
understanding of the biology. Single-nucleotide polymorphisms
can also be chosen from a region previously identified by linkage
study or microarray expression analysis. Intense effort has focused
on SNPs that alter protein function or gene expression. A
hierarchy for predicting a possible phenotypic expression for a
SNP has been proposed (Risch, 2000). It has been estimated that
there are perhaps 50000–250000 SNPs which confer a biological
effect, most of which are distributed in and around the 30000
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www.bjcancer.comgenes (Risch, 2001). Prediction of a biological effect is probably
more complicated than once argued; for instance, a synonymous
SNP, which does not alter the amino-acid sequence has been
shown to influence the stability of the DRD2 transcript, resulting in
alterated expression (Duan et al, 2003).
Since the majority of SNPs do not confer a phenotypic
alteration, but lie on ancestral haplotypes, a critical distinction
must be made between SNPs as genetic markers and causal factors
associated with a phenotypic effect. To date, the literature has
focused on SNPs that have a predicted or demonstrated functional
effect. A candidate gene approach that includes haplotype-tagging
SNPs investigates genetic variation across the gene or locus. Once a
haplotype has been confirmed as a marker for a phenotype, it is
necessary to analyse the component SNPs to determine the causal
variants. In some cases, it might be necessary to study additional
SNPs, to better define the haplotype structure in search of causal
variants. Attempts to by-pass this and pick only ‘functionally’
important SNPs limits the opportunity to ‘mark’ a gene or region.
Moreover, there is a certain amount of hubris to continue to expect
that picking individual SNPs is an effective strategy to identify
alterations in genes that could contribute to complex diseases,
such as cancer. No doubt, preclinical studies will suggest which
variants to study, but the technical and bioinformatics advances
have already generated a rich resource for study, which includes
many genes and SNPs, of which little is known.
STUDY DESIGN
Traditionally, two different methods have been applied to the study
of genetic variants in human disease. In SNP and haplotype studies,
the measure of effect is a change in risk, that is, attributable risk.
The results indicate a nonrandom distribution of genetic variants
between cases and controls. In general, a SNP finding is neither
necessary nor sufficient for the complex disease under study.
Firstly, in highly penetrant monogenic disorders, family linkage
analysis has been successful in identifying many rare genetic
disorders. So far, more than 1200 disease-causing genes have
been identified (http://www.ncbi.nlm.nih.gov:80/entrez/query.
fcgi?db¼OMIM). For complex diseases, such as most cancers, the
paucity of family pedigrees has limited the success of this strategy,
especially in search of moderate or low penetrance genes (Risch,
2001). Even in instances in which rare germ-line mutations in TP53
or VHL genes have been mapped, penetrance is not complete (i.e.,
the presence of a mutation does not necessarily lead to cancer); this
observation suggests that additional modifying genes as well as
environmental factors contribute to cancer even in the high-risk
setting. In studies of subjects with a monogenic disorder (i.e., cystic
fibrosis or chronic granulomatous disease), it has been possible to
identify modifying variants that influence the risk for well-defined
phenotypes (Foster et al, 1998; Garred et al, 1999).
The second strategy, which is more commonly employed, is the
genetic association study in unrelated subjects. Collection of larger
data sets of cases and controls permits investigation of SNPs and
haplotypes, which confer a moderate or low effect. Until recently,
the primary approach utilised has been the case–control design,
but, recently, many have advocated turning to population-based
cohort studies. Traditionally, case–control studies have been
designed to detect susceptibility loci and, rarely, protective alleles
(Risch and Merikangas, 1996; Risch, 2000).
ANALYTICAL ISSUES IN SNP STUDIES
Estimation of LD and construction of haplotypes represents
a powerful tool for conducting association studies (Gabriel
et al, 2002). Even if the extent of LD and the number of haplotypes
vary across the genome and between populations, it appears that
there is generally low haplotype diversity for each locus, with some
differences observed in separate populations (Daly et al, 2001).
Consequently, association studies can genotype a limited set of
SNPs that contribute to common haplotypes, with haplotype-
tagging SNPs (ht-SNPs) (Stram, 2003). Resequence analysis is
required to capture sufficient diversity in populations of unrelated
subjects, which can be analysed to infer haplotype structure across
the locus (Bonnen et al, 2002). Analysis with ht-SNPs saves money
and DNA, but requires new analytical tools to estimate the effect of
individual haplotypes on both the main effect (i.e., susceptibility or
outcome) and gene–gene interactions. Already several studies
have demonstrated the utility of haplotype analysis; for instance,
an association has been reported between haplotypes on chromo-
some 19 and basal cell carcinoma; similarly, haplotypes of the
Genotypes and inferred haplotypes
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a    B    c
A    B    C
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A    B    C
A    B    c
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A    b    C
A    B    C
A    B    c
A    B    C
A    b    C
A    B    C
A    b    C
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A    B    c
A    B    C
A    B    c
A    b    C
a    B    c
Individual Site 1 Site 2 Site 3
1.1 AA BB Cc
1.2 AA Bb CC
1.3 AA BB CC
1.4 Aa BB cc
2.1 AA Bb CC
2.2 AA BB Cc
3.1 AA BB Cc
3.2 AA Bb CC
Figure 1 Determination of haplotypes in unrelated and related subjects. Haplotype structure is determined in pedigrees on the basis of genotype analysis
at three different sites of a chromosomal region. The major and minor alleles are represented by A/a, B/b and C/c, respectively. The haplotypes can be
deduced from the data in the table, and follow classical Mendelian inheritance. Haplotypes can be inferred in unrelated subjects by applying statistical
algorithms to estimate haplotypes, based on genotype data. However, this will not determine a haplotype unequivocally, rather giving a haplotype with a
statistical probability of being correct. Although this approach is most widely used because of its cost effectiveness, other methods exist that will determine
haplotypes conclusively. On occasion, one can isolate DNA clones from a single chromosome for direct sequence analysis or selectively amplify using allele-
specific oligonucleotide primers.
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candidiasis, a life-threatening infection in patients with acute
leukaemia (Yin et al, 2002; Choi et al, 2003).
Association studies have been plagued by an inability to
consistently yield reproducible results. Several factors contribute
to this conundrum and are hotly debated among experts in the
field. Since replication is critical for acceptance of the causal
association between a SNP or haplotype and an outcome, it has
been argued that false-positive associations are better tolerated
than false negatives. Thus far, the problem has been that there have
been too many false positives. Some have argued that the execution
of a large number of tests, by definition, contributes to the high
rate of false positives, but others argue that the variables are not
independent, certainly not when considering haplotypes (Colhoun
et al, 2003; Lohmueller et al, 2003). Another factor for lacking
reproducibility is inadequately powered studies, both in the initial
and follow-up studies. Admixture of populations has been
advanced as a confounding factor, though the effect has been
demonstrated to be less than anticipated in published examples
(Wacholder et al, 2000). Still, genetic drift coupled with the rate
and genomic distribution of recombination and mutation events in
populations under different pressures will affect LD and, thus, the
potential to discover a given association (Frisse et al, 2001;
Colhoun et al, 2003; Lohmueller et al, 2003). Currently, alternative
remedies have been advanced that address novel statistical
analysis, Bayesian approaches and meta-analyses of published
studies. It is anticipated that current analytical tools will rapidly
evolve in response to revisitation of data sets.
SNPs IN CANCER RESEARCH
Genetic association studies with SNPs targeting cancer can be
divided into two broad categories, investigation of susceptibility
and of outcomes (see Table 1). The latter seeks to determine
prognostic information for survival, complications or response to
pharmacological intervention (i.e., pharmacogenomics). To date,
nearly all published studies have examined at most a few SNPs or
genes, and on a rare occasion variants within genes of a pathway or
related biological process, such as DNA repair enzymes (i.e., XRCC1
and XRCC3) or xenobiotic metabolism genes (i.e., NAT1 and
NAT2). Though early in the study of SNPs and cancer, technical
and bioinformatics advances make it possible to dramatically
increase the number of genes applied to a study. It is important to
bear in mind that SNP studies require replication prior to
acceptance, and certainly before clinical implementation. There-
fore, it is critical to consider the current published literature as very
preliminary analysis of what will certainly be a complex process.
Susceptibility to cancer
The aetiology of a specific cancer is probably associated with a set
of genetic variants, many of which could adversely interact with
environmental factors. So far, the initial studies of single genes
have established a paradigm that will eventually examine gene–
gene interactions. Studies in lung cancer have interrogated genes
important for tobacco metabolism and nicotine addiction. The
approach focuses on the interaction of a strong environmental
carcinogen, and seeks to identify genetic variants that confer
susceptibility or protection from tobacco smoke. In this regard, the
gene–environment interaction represents a stress on the host, and
perhaps intensifies the phenotypic effect of the ‘causal’ SNP. For
instance, the myeloperoxidase gene, MPO, has been extensively
studied, yielding moderately reproducible data in studies with
Caucasians. The functional consequence of the G to A transition at
 463 of the proximal promoter leads to reduced MPO mRNA
expression. Individuals homozygous for the A allele have a
significantly lower risk for developing lung cancer compared to
individuals with two G alleles (London et al, 1997; Cascorbi et al,
2000; Le Marchand et al, 2000).
It is notable that, in one context, the SNP or haplotype can be
protective, whereas, in another, confer increased susceptibility. For
example, one of the strongest cases can be made for the association
of polymorphisms in N-acetyltransferase 2 (NAT2) with bladder and
colon cancer. NAT1 and NAT2 encode enzymes that are important
for biotransformation of aromatic and heterocyclic amines, known
carcinogens. The risk of developing urinary bladder cancer is
particularly high in the slowest NAT2 acetylator phenotype, and is
exacerbated by the history of smoking. On the other hand, for
heterocyclic amine-related colon cancer, NAT2 rapid acetylator
phenotype confers a higher risk (Golka et al, 2002; Hein, 2002).
Outcome and SNPs
Variants can be associated with outcome and, thus, could be applied
to clinical decision making. For instance, genetic variants could alter
the risk for metastatic or aggressive tumour. To date, few studies have
unequivocally shown the importance of germ-line variants as
prognostic markers, but, since a tiny percentage of the known genes
have been adequately studied, investigation of SNPs remains active.
So far, preliminary results suggest that SNPs in CYP3A4 are associated
with long-term outcome in prostate cancer. The promoter SNP A-
290G in CYP3A4, a gene involved in the oxidation of testosterone to
2B-, 6B, or 15B-hydroxytestosterone, appears to be associated with the
severity of disease, as measured by TNM stage and Gleason grade.
The effect is stronger in older men without a family history of prostate
cancer (Rebbeck et al, 1998; Paris et al,1 9 9 9 ) .
Pharmacogenomics is the study of the inherited basis of
interindividual differences in drug response. It has been estimated
that inherited differences account for inter individual variation
observed in drug response (Kalow et al, 1998). There have been
two parallel approaches in pharmacogenomics. One approach has
been the search for genetic variants that are associated with
severe adverse effects, which, in turn, can be used to screen for
individuals who should not receive the drug in question.
The second approach has focused on identifying markers that
predict drug efficacy. The former has been widely embraced by the
commercial sector, whereas the latter has been more tepidly
pursued. Nevertheless, the promise of pharmacogenomics is that
it could lead to tailored drug therapy, which some have dubbed
as ‘individualised medicine.’ The harsh reality is that the
choice facing an individual will have to be made on the basis
of risk assessment gathered from large, population-based studies.
Candidate genes have focused on drug metabolism, that is,
uptake, activation, degradation and excretion, to identify SNPs that
are associated with life-threatening adverse reactions. Armed with
validated SNPs and haplotype markers that associate with adverse
drug reactions, clinicians could perform screening tests and, if
indicated, choose alternate therapy. However, application to
clinical medicine will be daunting, since many SNPs will identify
risk factors that have only moderate-to-low penetrance. In other
words, the clinician will be faced with assessing the overall risk for
adverse effects, which will have to be weighed against potential
benefits as well as the availability of alternative therapies.
Table 1 Examples of genes and associations
Gene Association
Cancer susceptibility
Myeloperoxidase, MPO Lung cancer
N-acetyltransferase 1, NAT1 Bladder cancer




Thiopurine S-methyltransferase, TPMT Haematological toxicity
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the story of acute childhood leukaemia and variants in the
thiopurine S-methyltransferase (TPMT) gene. The protein encoded
by the TPMT gene is a catalyst for S-methylation of thiopurines,
commonly used in the treatment of haematopoietic malignancies
and autoimmune disorders (e.g., azathiprine, 6-mercaptopurine
and thioguanine). Thiopurine drugs are activated to thioguanine
nucleotides, which are cytotoxic. Cytotoxicity can be intended (e.g.,
antileukaemia therapy), but if prolonged, life-threatening. It was
discovered that several rare variants in the TPMT gene correlated
with decreased activity; homozygous individuals suffered substan-
tial haematopoietic toxicity (Krynetski et al, 1996). Recently, it has
been reported that children with inactivating TPMT variants are at
a greater risk for relapse, perhaps reflecting inadequate adminis-
tration of thiopurines (Black et al, 1998). Pediatric leukaemia
patients with TPMT variants, who receive cranial irradiation, have a
greater likelihood for secondary brain tumours.
The search for markers useful for predicting drug efficacy has
focused on the cytochrome P-450 system and, specifically, the
CYP2D6 gene. This gene contributes to the metabolism of many
anticancer agents. Common SNPs in CYP2D6 impair the activity of
CYP2D6 and perhaps alter the pharmacokinetics of anticancer
drugs (Kroemer and Eichelbaum, 1995). In some circumstances,
the impaired CYP2D6 activity actually enhances the drug effect,
but perhaps at the expense of enhanced toxicity.
EPIGENETIC CHANGES AND GENETIC VARIATION
Genomic instability has been characterised in many human cancers
and its signature is the pattern of sequence alterations, frequently
resulting in allelic imbalance. Until recently, efforts to capture
global patterns of genomic imbalance have employed microsatel-
lites, but the utility of dense SNP markers has been demonstrated in
proof-of-principle studies. Global patterns of genomic imbalance
can be detected by allelotyping of cancers, and point to regions
where allelic imbalance could contribute to cancer. Since loss of
heterozygosity (LOH) within one or more chromosomal region is a
common form of allelic imbalance, sites of LOH can be investigated
for the presence of tumour-suppressor genes. Studies in bladder,
lung and prostate cancers have discovered previously unknown
allelic imbalances in multiple sites using SNPs for LOH analysis
(Lindblad-Toh et al, 2000). It is likely that patterns of LOH, through
SNP analysis, could have diagnostic and prognostic implications.
Specific LOH pattern could be correlated with expression array
profiles to identify causal variants.
THE FUTURE OF SNPS AND HAPLOTYPES IN CANCER
The analysis of SNPs and haplotypes in cancer research has
pleotropic implications for clinical and public health issues, as well
as cancer biology. New findings can lead to targeted therapies for
cancer intervention and prevention. The initial excitement of
applying genetic variation to cancer has yielded to the realisation
that a complex set of challenges lie ahead, which will tax the scientific,
clinical and social adaptation of the new era of genomic medicine.
Already, there are examples in pharmacogenomics and cancer
susceptibility that have established the importance of this field, but
it must be emphasised that they represent the beginning. The next
decade could witness the investigation and implementation of genetic
variation in the diagnosis, prevention and treatment of cancer.
The promise of SNP and haplotype analysis is that it will yield
insights into exposure and cancer, and specifically lay the foundation
for primary preventive strategies pertaining to lifestyle (i.e.,
alterations in diet, exercise and weight control) and chemopreven-
tion. In turn, secondary prevention will address screening and public
health measures designed to identify and intervene in high-risk
individuals. The latter will become more complicated as we integrate
information about pharmacogenomics, second malignancies and
long-term complications. This is particularly complex because the
consequences of one set of SNPs could have deleterious con-
sequences for one outcome, but yet be advantageous for another.
A major challenge ahead is the development of more
sophisticated analytical tools for handling the expanding data.
We will need to address the complex issue of gene–gene
interactions, particularly if profiles of SNPs are to be used in the
clinical venue. At the same time, it is imperative to develop
structures to include more individuals in population-based
studies, yet preserve both confidentiality and individuality. In
many respects, this is the most daunting challenge, to derive the
information to interpret the significance of specific SNPs and
haplotypes from population-based studies, yet apply the informa-
tion to the individual. It could have a significant impact on the
economics of medical practice.
In the end, the clinical application of what we learn from SNP
studies will probably require a major shift in the paradigm of
practice. Practitioners could make treatment decisions or give
advice based on an assessment of risk. To begin to address the
central issues of SNPs, haplotypes and cancer, detailed knowledge
of the scope and pattern of genetic variation will be required,
namely SNPs, haplotypes and linkage disequilibrium for genes and
pathways critical to cancer in different populations.
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